UCB appoints new head of Bone Patient Value Unit

UCB has announced the appointment of Pascale Richetta as its newest executive vice-president and member of the executive committee.

Ms Richetta will head the company's Bone Patient Value Unit, a position that was created last year. In this role, she will take a leading role in the development of the osteoporosis drug romosozumab, which is being co-developed with Amgen.

Richetta boasts more than 20 years of commercial experience managing traditional pharmaceuticals and complex biologics. She joins UCB from AbbVie, where she served as vice-president for western Europe and Canada.

Iris Loew Friedrich previously led the Bone Patient Value Unit in addition to her responsibilities as chief medical officer and head of the development and medical practices.

Jean-Christophe Tellier, UCB's chief executive officer, said: "We are very happy to welcome Pascale on our team to lead our Bone Patient Value Unit and take our investigational osteoporosis drug romosozumab through its next development steps."

This comes after the company received approval from the European Commission for Briviact, its promising new epilepsy treatment, earlier this week.